BCV
AVTX icon

Banque Cantonale Vaudoise’s Avalo Therapeutics AVTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-338
Closed -$4K – 765
2024
Q2 		$4K Hold
338
– – ﹤0.01% 963
2024
Q1 		$2K Buy
+338
New +$1.82K ﹤0.01% 965
2023
Q4 		– Sell
-338
Closed -$10K – 1030
2023
Q3 		$10K Buy
+338
New +$15.1K ﹤0.01% 1111

Other funds holding AVTX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Banque Cantonale Vaudoise's AVTX Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Avalo Therapeutics (AVTX) in Q3 2024, closing a stake of 338 shares — an estimated $4K sold.

Banque Cantonale Vaudoise first reported a position in AVTX in Q3 2023 and held it in 3 quarters. The position peaked at $10K in Q3 2023. 29 funds tracked by Wall St. Rank hold AVTX as of Q3 2024.

  • Banque Cantonale Vaudoise reported no remaining Avalo Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 338 Avalo Therapeutics shares in Q3 2024, an estimated $4K.
  • Banque Cantonale Vaudoise first reported a position in Avalo Therapeutics in Q3 2023 and held it in 3 quarters.
  • Banque Cantonale Vaudoise's Avalo Therapeutics position peaked at $10K in Q3 2023.
  • 29 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.